Valuation: BioNTech SE

Market Cap 19.83B 119B 22.1B 18.33B 16.61B 31.02B 2,105B 31.4B 219B 87.32B 1,102B 82.95B 81.19B 3,497B P/E 2026 *
-13.5x
P/E 2027 * -14.7x
Enterprise Value 8.73B 52.31B 9.74B 8.08B 7.31B 13.66B 927B 13.83B 96.55B 38.46B 485B 36.53B 35.76B 1,540B EV / Sales 2026 *
4.92x
EV / Sales 2027 * 5.61x
Free-Float
96.06%
Yield 2026 *
-
Yield 2027 * -
1 day-1.96%
1 week+1.36%
Current month-9.12%
1 month-10.63%
3 months-2.03%
6 months-10.27%
Current year-11.61%
1 week 27.6
Extreme 27.6
30.33
1 month 27.6
Extreme 27.6
32.15
Current year 25.78
Extreme 25.78
41
1 year 25.78
Extreme 25.78
41
3 years 25.78
Extreme 25.78
49.05
5 years 25.78
Extreme 25.78
66.08
10 years 25.78
Extreme 25.78
66.08
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 59 2017-12-31
Chief Executive Officer 61 2008-06-01
Director of Finance/CFO - 2025-06-30
Director TitleAgeSince
Chairman 56 2008-06-01
Director/Board Member 69 2008-06-01
Director/Board Member 65 2017-12-31
Change 5-day change 1-year change 3-year change Capi.($)
-1.96%+1.36% - - 21.87B
+0.65%-3.36%+36.98%+60.50% 63.48B
+1.76%+1.27%+11.82%+81.21% 54.55B
-0.94%+0.99%+10.45%+100.19% 53.59B
+2.76%+0.87%+27.92%+55.07% 44.75B
+2.00%-3.39%+17.83%+119.04% 41.62B
+1.34%-2.86%+224.43%+914.08% 39.91B
+0.64%-3.95%+11.15%+45.57% 32.47B
+29.06%+47.63%+107.12%+92.73% 26.7B
-2.12%-0.13%+23.56%-10.50% 23.36B
Average +3.29%+0.05%+52.36%+161.99% 42.27B
Weighted average by Cap. +2.60%+0.19%+48.04%+161.01%

Financials

2026 *2027 *
Net sales 1.78B 10.63B 1.98B 1.64B 1.49B 2.78B 188B 2.81B 19.62B 7.82B 98.61B 7.42B 7.27B 313B 1.8B 10.76B 2B 1.66B 1.5B 2.81B 191B 2.85B 19.87B 7.91B 99.83B 7.52B 7.36B 317B
Net income -1.46B -8.73B -1.62B -1.35B -1.22B -2.28B -155B -2.31B -16.11B -6.42B -80.96B -6.1B -5.97B -257B -1.28B -7.68B -1.43B -1.19B -1.07B -2.01B -136B -2.03B -14.17B -5.65B -71.23B -5.36B -5.25B -226B
Net Debt -11.1B -66.46B -12.37B -10.26B -9.29B -17.36B -1,178B -17.57B -123B -48.86B -616B -46.41B -45.43B -1,957B -9.75B -58.41B -10.87B -9.02B -8.17B -15.26B -1,035B -15.44B -108B -42.94B -542B -40.79B -39.93B -1,720B
Projected Income Statement - Annual - BioNTech SE
Logo BioNTech SE
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.
Employees
7,807
Date Price Change Volume
26-10-27 R$29.01 -1.96% 207
26-10-26 R$29.59 +6.98% 2,930
26-10-23 R$27.66 -4.62% 2,756
26-10-22 R$29.00 +1.33% 188
26-10-21 R$28.62 +1.67% 200
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
MarketScreener Ratings - BioNTech SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
78.94EUR
Average target price
104.16EUR
Spread / Average Target
+31.94%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - BioNTech SE